Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab
CNTO1959ISD3001
Phase 3 small_molecule active
Quick answer
Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab for Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD) is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active